@inproceedings{inproceedings, title  = {{2-year open-label extension phase results from the pivotal phase 3 study of denosumab in patients with metastatic castration-resistant prostate cancer (CRPC) previously treated with denosumab or zoledronic acid}},

 url = {{}},

 year = {{2013}},

 month = {{4}},

 author = {{Kueppers F and Fizazi K and Brown J and Carducci M and Shore N and Sieber P and Karsh L and Wei R and Goessl C}},

 volume = {{111}},

 journal = {{BJU INTERNATIONAL}},

 pages = {{91-92}},

 note = {{Accessed on 2024/12/27}}}